Endocrinology doi: 10.1210/en.2015-2036
Jasmaine D. Williams,* Abhishek Aggarwal,* Srilatha Swami, Aruna V. Krishnan, Lijuan Ji, Megan A. Albertelli, and Brian J. Feldman
Department of Pediatrics (J.D.W., A.A., A.V.K., L.J., B.J.F.), Stanford School of Medicine, Stanford, California 94305; Department of Medicine (S.S.), Stanford School of Medicine, Stanford, California 94305; Department of Comparative Medicine (M.A.A.), Stanford School of Medicine, Stanford, California 94305; and Stanford Cancer Institute (B.J.F.), Stanford School of Medicine, Stanford, California 94305
A poor Vitamin D Receptor is not noticed by vitamin D tests
- Metastatic Cancer probably reduced by vitamin D - many studies
- Overview Cancer and vitamin D
- Pancreatic Cancer massively deregulates the local Vitamin D receptors and CPY24A1 – July 2014
- Vitamin D dose size needed – VitD testing tells only a portion of the story – Jan 2016
- Benefits of Vitamin D often limited by genes
- Breast cancer spreads to bone if poor vitamin D Receptor (no surprise) – Oct 2022
- Some breast cancers may be treated RNA changes caused by Vitamin D – March 2022
- Breast Cancer, Vitamin D, and genes – Welsh Nov 2021
- After lactation Vitamin D levels are low, increased risk of Breast Cancer, vitamin D should decrease risk – Aug 2021
- Breasts process Vitamin D and change gene activation, might prevent breast cancer if given more Vit. D – July 2021
- Breast cancer associated with Vitamin D Receptor (14th study) – Oct 2019
- After breast cancer treatment 4,000 IU of Vitamin D was not enough to help if have poor Vitamin D receptor – June 2019
- Breast Cancer death 1.8 X more likely if poor Vitamin D Receptor – April 2019
- Breast Cancer and Vitamin D review – March 2018
- Women with Breast Cancer were 16.9 times more likely to have a poor Vitamin D Receptor – Jan 2019
- Cancer treatment by Vitamin D sometimes is restricted by genes – Oct 2018
- Two chemicals increase the Vitamin D receptor and decrease the growth of breast cancer cells in the lab - March 2018
- Breast Cancer reduces receptor and thus blocks Vitamin D to the cells – several studies
- Vitamin D receptor as a target for breast cancer therapy (abstract only) – Feb 2017
- Breast Cancer was 4.6 times more likely if have a poor Vitamin D Receptor – Dec 2016
- Increased Breast Cancer metastasis if low vitamin D or poor VDR – Feb 2016
- Increased risk of some female cancers if low vitamin D (due to genes) – meta-analysis June 2015
- Vitamin D receptor in breasts and breast cancer vary with race – March 2013
- Breast Cancer incidence change by 40 percent with vitamin D receptor genes – Oct 2012
- Genes breast cancer and vitamin D receptor - Sept 2010
Vitamin D Receptor category has the following
Vitamin D tests cannot detect Vitamin D Receptor (VDR) problems
A poor VDR restricts Vitamin D from getting in the cells
It appears that 30% of the population have a poor VDR (40% of the Obese )
Several diseases protect themselves by deactivating the Vitamin D receptor. Example: Breast Cancer
- - - - - - - -
The Vitamin D Receptor is associated with many health problems
Some health problems, such as Breast Cancer, Diabetes, and COVID protect themselves by reducing VDR activation
A poor VDR is associated with the risk of 55 health problems click here for details
The risk of 48 diseases at least double with poor VDR as of Jan 2023 click here for details
Some health problem, such as Breast Cancer reduce the VDR
VDR at-home test $29 - results not easily understood in 2016
There are hints that you may have inherited a poor VDR
Compensate for poor VDR by increasing one or more:
|1) Vitamin D supplement Sun|
| Vitamin D in the blood |
and thus in the cells
|2) Magnesium||Vitamin D in the blood |
AND in the cells
|3) Omega-3||Vitamin D in the cells|
|4) Resveratrol||Vitamin D Receptor|
|5) Intense exercise||Vitamin D Receptor|
|6) Get prescription for VDR activator|
|Vitamin D Receptor|
|7) Quercetin (flavonoid)||Vitamin D Receptor|
|8) Zinc is in the VDR||Vitamin D Receptor|
|9) Boron||Vitamin D Receptor ?, |
|10) Essential oils e.g. ginger, curcumin||Vitamin D Receptor|
|11) Progesterone||Vitamin D Receptor|
|12) Infrequent high concentration Vitamin D|
Increases the concentration gradient
|Vitamin D Receptor|
|13) Sulfroaphane and perhaps sulfur||Vitamin D Receptor|
|14)Butyrate especially gut||Vitamin D Receptor|
Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above
Far healthier and stronger at age 72 due to supplements Includes 6 supplements that help the VDR
The following is just text - no formatting and none of the charts in the PDF
Patients with breast cancer (BCa) frequently have preexisting vitamin D deficiency (low serum 25- hydroxyvitamin D) when their cancer develops. A number of epidemiological studies show an inverse association between BCa risk and vitamin D status in humans, although some studies have failed to find an association. In addition, several studies have reported that BCa patients with vitamin D deficiency have a more aggressive molecular phenotype and worse prognostic indicators. However, it is unknown whetherthis association is mechanistically causative and, if so, whether it results from systemic or tumor autonomous effects of vitamin D signaling. We found that ablation of vitamin D receptor expression within BCa cells accelerates primary tumor growth and enables the development of metastases, demonstrating a tumorautonomouseffectof vitamin DsignalingtosuppressBCametastases.Weshowthat vitamin D signaling inhibits the expression of the tumor progression gene Id1, and this pathway is abrogated in vitamin D deficiency in vivo in 2 murine models of BCa. These findings are relevant to humans, because we discovered that the mechanism of VDR regulation of Inhibitor of differentiation 1 (ID1) is conserved in human BCa cells, and there is a negative correlation between serum 25-hy- droxyvitamin D levels and the level of ID1 in primary tumors from patients with BCa. (Endocrinology 157: 0000-0000, 2016)
min D likely has pharmacological effects that are distinct from the pathophysiology of vitamin D deficiency.
Provocatively, low vitamin D levels are associated with worse prognostic indicators and outcomes in patients with BCa (9-11). Because vitamin D deficiency is common in patients diagnosed with BCa (1, 10, 12-14), elucidating the cause of the association between poor outcomes and vitamin D deficiency promises to have a significant impact on improving care for patients with BCa, including enabling the development of novel therapeutic approaches. Metastatic disease is the primary cause of treatment failure and poor prognosis in patients with BCa. However, although there are intriguing data suggesting that systemic vitamin D levels affect the growth of BCa cells that are already metastatic (15, 16) and BCa cells that are directly seeded into distal sites (17), the effect of vitamin D deficiency on the critical step in tumor progression from non-metastatic to metastatic is unknown. Finally, whether the mechanisms by which vitamin D deficiency and VDR signaling modulates BCa growth and metastasis are systemic or tumor autonomous is also unclear. Therefore, in this study, we tested the impact of vitamin D deficiency on BCa growth and investigated the tumor autonomous effect of VDR signaling on BCa progression and metastasis.
Materials and Methods
All animal studies were approved by the Stanford Institutional Animal Use and Use Committee.
All clinical samples were obtained in accordance with a Stanford Institutional Review Board approved protocol, which included informed consent.
Five to 6-week-old female wild-type BALB/c mice were purchased from The Jackson Laboratory. AIN76 diets containing 500-IU vitamin D/kg were used as standard diets and compared with vitamin D-deficient diets which had 25-IU/kg diet. All diets were obtained from Research Diets, Inc. Tumors were inoculated into the left inguinal mammary fat pad using 1 X 105 cells sus- pended50:50matrigel (ThermoFisher) and PBS. Bioluminescent imaging (BLI) was performed once a week using the IVIS 200 (Caliper) imaging system at the Stanford Small Animal Imaging Facility as described (18, 19). Tumor volume was estimated by measuring 2 tumor diameters using a vernier calipers. Lungs, liver, and spleen were subjected to ex vivo BLI to map metastatic lesions and histopathological confirmation.
Measurement of 25(OH)D
Mouse serum 25(OH)D levels were measured as described (20). Human serum 25(OH)D levels were measured by mass spectroscopy in the Stanford Clinical Laboratories.
Generation of stable Vdr knockdown (KD) and Rescue cell lines
Short hairpin RNAs directed against mouse Vdr (Sigma-Al- drich) or control vector were stably transfected into 168FARN- luc cells (a gift from Fred Miller, Wayne State University) and selected for puromycin resistance clonal selection from a single cell. The cells were then transfected with a VDR expression plasmid or empty vector (pEF6; Thermo Fisher) control and selected with puromycin and blasticidin.
Student’s t test was computed to determine statistically significant differences between 2 groups. For comparisons between more than 2 groups, ANOVA was performed followed by Tukey’s post hoc test. Spearman’s test was performed to compute correlation analysis. P < .05 was considered statistically significant. GraphPad Prism (GraphPad Software, Inc) was used to perform statistical calculations and for plotting graphs.
For antibodies, please see Table 1. Additional Materials and Methods are detailed in the Supplemental Materials and Methods.
Results and Discussion
Diet-induced vitamin D deficiency promotes BCa growth in vivo
To understand the impact of systemic vitamin D deficiency on BCa progression, we generated a mouse model of vitamin D deficiency by placing wild-type mice on a standard chow diet (control, 500-IU vitamin D3/kg diet) or on a low vitamin D diet (LD25, 25 IU/kg) for 10 weeks. Ingestion of the LD25 diet caused a statistically significant decrease in serum 25(OH)D levels compared with control mice (Supplemental Figure 1). We orthotopically seeded the vitamin D-deficient and control cohorts with primary MMTV-Wnt1 tumor cells (21) into the fourth mammary fat pad of the mice. We found that vitamin D-deficient mice developed mammary tumors that were palpable an average of 7 days earlier than control mice. Importantly, vitamin D deficiency also accelerated tumor growth, resulting in a significant increase in the mean tumor volume after 6 weeks compared with tumors grown in mice fed the control diet (Figure 1A).
Tumor autonomous effects of vitamin D/VDR signaling
We next explored whether the impact of vitamin D signaling on tumor growth was tumor autonomous or resulted from systemic effects. First, we examined 2 BCa cell lines that stably express luciferase, 168FARN and 4T1 (22), for their in vivo growth characteristics and VDR expression levels. As previously reported (23), we found that the tumors generated in vivo from 4T1 cells grew more rapidly and developed distal metastases, whereas the 168FARN tumors grew more slowly and did not macro- metastasize outside of the primary tumor site (Figure 1B). Intriguingly, we discovered that the highly aggressive and metastatic 4T1 cell line has significantly lower levels of VDR expression compared with the less aggressive, metastatic-deficient 168FARN cell line (Figure 1C).
In order to test whether the observed difference in aggressiveness between the cell lines is regulated by the differences in vitamin D/VDR signaling in the tumor cells, we generated a 168FARN cell line with stable Vdr knockdown (VDR KD). We confirmed that Vdr KD results in a substantial decrease in VDR levels compared with the vector control cells selected in parallel (Figure 1D). To validate that this level of Vdr KD is functionally relevant, we treated the VDR KD and vector control cell lines with calcitriol. A robust induction in mRNA expression of the classic calcitriol target gene, Cyp24A1, was observed in control cells, whereas this functional response was significantly diminished in VDR KD cells, demonstrating the attenuation of VDR signaling (Figure 1E). To establish that any functional differences between the vector control and VDR KD cell lines were specifically due to inhibition of Vdr expression, we rescued Vdr expression in the VDR KD line by stably integrating a Vdr expression vector into
the VDR KD cell line (VDR Rescue), which rescued both VDR levels and function (Figure 1, D and E).
To test the effect of Vdr KD on cell migration, an early step in BCa progression, we used a transwell migration assay (24, 25). We discovered that VDR KD cells exhibit a notable increase in the number of migratory cells compared with control cells and this phenotype was rescued in the VDR Rescue cells (Figure 1F). These data indicate that VDR signaling is functionally relevant to regulating BCa migration ex vivo and therefore may impact BCa progression and metastasis.
Loss of vitamin D/VDR signaling promotes BCa metastasis in vivo
We next examined whether there are tumor autonomous effects of vitamin D signaling in vivo using the VDR KD cells. We established mammary tumors in BALB/c mice by orthotopic injections of the luc-labeled control, VDR KD, and VDR Rescue cell lines and followed tumor appearance and growth over 4 weeks by BLI (26). We found that VDR KD tumors grew significantly faster than control or VDR Rescue cells in vivo (Figure 2A). This striking pattern remained consistent until the endpoint of the study when the mice with VDR KD tumors needed to be euthanized for morbidity (Figure 2B). Primary tumors were harvested, measured, weighed, and imaged (Figure 2, C and D, and Supplemental Figure 2). These results confirmed the in vivo BLI signal data that the VDR KD tumors were substantially larger than control and VDR Rescue tumors. Remarkably, ex vivo BLI imaging (Figure 2E) and direct histology (Supplemental Figure 3) revealed that 60% of the mice with VDR KD tumors had metastatic spread to the liver. This represents a particularly significant finding as no evidence of macrometastatic tumor spread was found in the control or rescue groups (Figure 2E and Supplemental Figure 3). Our results indicate that loss of vitamin D/VDR signaling is sufficient to convert the cells from nonmetastatic to metastatic.
Vitamin D/VDR regulates Id1 expression in BCa
In order to elucidate the mechanisms by which vitamin D/VDR signaling exerts an inhibitory effect on tumor progression, we performed expression profiling using PCR arrays comparing tumors that developed in the diet-induced vitamin D-deficient mice with tumors that developed in mice fed the standard chow. In addition, we compared the expression profile of the VDR KD cells with control cells. We then compared the differentially (>2- fold) expressed genes to identify genes with similarly altered expression profiles in both tumors from vitamin D- deficient mice and VDR KD cells (Supplemental Table 1). These studies revealed Id1 as significantly up-regulated in both the tumors that developed in vitamin D-deficient mice and the VDR KD cells, suggesting that Id1 is repressed by VDR signaling in BCa. This ’hit’ was of particular interest because of the role of Id1 in BCa progression (27) and most intriguing because calcitriol was found to induce, rather than repress, ID1 expression in a colon carcinoma cell line (28). We validated that Id1 expression was up-regulated in both tumors from vitamin D-deficient mice as well as in the VDR KD cells (Figure 3, A and B ).
To test whether the regulation of Id1 by VDR is ligand dependent in BCa cells, we treated 168FARN cells with calcitriol and showed that this treatment represses the expression of Id1 (Figure 3C). We also found that calcitriol treatment significantly decreases Inhibitor of differentiation 1 (ID1) protein levels in a dose-dependent manner (Figure 3D). This suppression of Id1 by calcitriol treatment was substantially abrogated in the VDR KD cells (Figure 3D). Interestingly, basal levels of ID1 protein expression were significantly increased in the VDR KD cell line relative to control cells (Figure 3D) and the VDR Rescue cell line had lower levels of ID1 (Figure 3E; reprobed Western blot from Figure 1D). These results suggest that VDR might directly regulate Id1 in BCa cells and that basal endogenous levels of VDR suppress Id1 expression. Therefore, we investigated the promoter and proximal region of the Id1 gene for a negative vitamin D response element (nVDRE) that is functional in BCa cells. We transfected cells with a construct containing an approximately 1.5-kb fragment of the Id1 promoter and proximal region cloned into a luciferase reporter vector and found that calcitriol treatment of the transfected cells results in decreased luciferase activity (Figure 3F), whereas VDR KD increased luciferase levels (Supplemental Figure 4). Using luciferase reporter vectors with sequential deletions, we mapped a nVDRE to approximately 1 kb upstream of the Id1 transcriptional start site as functionally relevant in BCa cells (Figure 3F), the same nVDRE that is active in murine osteoblasts (29). Using chromatin immunoprecipitation of VDR on the endogenous nVDRE, we confirmed that calcitriol treatment enriches VDR occupancy of this element in 168FARN cells (Figure 3G).
We next tested whether the regulation of Id1 is the mechanism underlying the effect of vitamin D/VDR signaling to inhibit tumor cell migration and metastasis. In the transwell migration assay, KD of Vdr expression increased cell migration, as we showed previously in Figure 1F. Importantly, we discovered that KD of Id1 in VDR KD cells abolished the increase in cell migration seen in VDR KD cells, reducing the number of cells migrating back to control levels (Figure 3H).
Vitamin D/VDR regulation of ID1 is conserved in human BCa
To determine whether the findings from our mouse models are relevant to human BCa, we first tested whether ID1 expression is modulated by calcitriol treatment in the widely studied human breast adenocarcinoma cell line MDA-MB-231 (30). We found that calcitriol robustly down-regulated ID1 mRNA (Figure 4A) and protein levels (Figure 4B). Next, we searched the sequence of the human ID1 gene in silico and identified a DNA element approximately 1 kb upstream of the ID1 transcriptional start site with 98% nucleotide identity with the region containing the murine nVDRE (Supplemental Figure 5). Using a lu- ciferase reporter vector containing the human ID1 promoter and 1.3 kb of the upstream proximal region, we confirmed that the conserved nVDRE regulatory element in ID1 is functional in human BCa cells (Figure 4C).
In order to test whether our findings are relevant to patients with BCa, we obtained permission from our IRB and were generously granted access by the independent investigators of a recently completed clinical trial (NCT01472445) to deidentified data in order to examine the relationship between circulating 25(OH)D levels and tumor ID1 expression levels in patients undergoing BCa resections. This study was a randomized, double blind clinical trial in women with newly diagnosed BCa. Vitamin D3 was administered orally in the neo-adjuvant period to women scheduled for surgical resection of their tumors, with the intervention occurring during the 1- to 6-week neo-adjuvant interval before surgery. Subjects were randomly assigned to receive either 400 or 10 000 IU/d of vitamin D3 in a 1:2 ratio, respectively. This enabled us to analyze the relationship between a patient’s circulating 24(OH)D level and ID1 expression levels in their tumor at the same point in time (at surgical resection).
We found that serum 25(OH)D levels at the time of surgery were negatively associated with ID1 expression levels in the corresponding tumors (Spearman correlation coefficient r = -0.579, P < .001), with every 10-ng increase in circulating 25(OH)D levels being associated with a 20% reduction in ID1 expression levels in the tumor (Figure 4D). These results indicate that the relationship between Id1 expression and vitamin D status/VDR signaling that we identified in our mouse studies is conserved in humans and is relevant to patients with BCa.
Although many studies have investigated the effects of the administration of calcitriol or vitamin D analogs as a therapeutic approach in BCa (1), relatively less attention has been focused on specifically evaluating the detrimental effects of vitamin D deficiency on BCa progression and to metastasis. Our results show that dietary vitamin D deficiency accelerates the growth of BCa tumors. Further, we discovered that attenuated vitamin D signaling due to Vdr ablation enhances tumor progression and, importantly, is sufficient to enable metastases, which are the primary cause of treatment failure and death for patients with BCa.
We also discovered that, although circulating 25(OH)D has many systemic effects (1), a critical mechanism for vitamin D signaling to inhibit BCa progression is a tumor autonomous activity that suppresses Id1 expression. Interestingly, Sherman et al (31) found a tumor cell nonautonomous mechanism for VDR signaling to inhibit pancreatic ductal adenocarcinoma progression and Fernandez-Garcia et al (28) found that calcitriol induces, rather than inhibits, Id1 expression in a colon carcinoma cell line. Lungchukiet et al found that VDR tumor autonomously inhibits ovarian cancer invasion and metastasis through both ligand dependent and independent mechanisms (32). These distinctions with our study indicate that vitamin D signaling is highly context specific.
Significantly, our results demonstrate that, in BCa cells, VDR regulation of ID1 expression is mechanistically conserved in humans and that there is a negative association between circulating 25(OH)D levels and the expression of ID1 in primary tumors from BCa patients. We believe these findings contribute to the cause of the epidemiological association between low circulating 25(OH)D levels and poor prognosis in patients with BCa. In addition, our data suggest that correcting vitamin D deficiency in BCa patients may have beneficial effects to inhibit BCa progression and improve prognosis.
We thank members of the Feldman Laboratory for helpful discussions. We also thank David Feldman and Melinda Telli (Stanford University) for providing the trial data, Bonnie King (Stanford University) for providing 4T1-luc cells, and Fred Miller (Wayne State University) for providing 168FARN-Luc cells. B.J.F. is the Bechtel Endowed Faculty Scholar.
Address all correspondence and requests for reprints to: Brian J. Feldman, MD, PhD, Stanford University School of Medicine, Lokey Stem Cell Research Building, 265 Campus Drive, Stanford, CA 94305-5457. E-mail: feldman at stanford.edu.
J.D.W. was supported by a Stanford DARE (Diversifying Academia, Recruiting Excellence) fellowship and the National Institutes of Health Grant T32 CA09302. The work was supported by grants from the Stanford Cancer Institute, California Breast Cancer Research Program (19IB-0103), and the NIH Director’s New Innovator Award DP2 OD006740 (to B.J.F.).
Disclosure Summary: The authors have nothing to disclose.
References in PDF
|6224 visitors, last modified 09 Aug, 2017,